Prospectus For Establishment of a DSCSA Governance Body

A session investigates the drivers of these shortages and ways to mitigate them.

Nicholas Saraceno offers an overview of the legislation and how it impacts the pharma supply chain.

A cohort study of cancer drugs analyzes where the priorities of pricing policies should lie.

Dave DeJean provides his expert insight on lessons he’s learned from his plethora of time in the industry, along with an outlook on where the pharma supply chain stands in adhering to the Drug Supply Chain Security Act (DSCSA).

Addressing the bottlenecks in cell and gene therapy manufacturing through a well-designed artificial intelligence approach is essential to avoiding data siloes.

Is the potential of a more formal policy integration for health issues and disease prevention a scary suggestion or a good Idea?